Altice Dominicana and iBASIS Renew International Voice Services Outsourcing Deal
iBASIS, the leading provider of communications solutions for operators and digital players worldwide, and Altice Dominicana, one of the leading mobile networks in the Dominican Republic, announced today that they have renewed their successful outsourcing agreement for voice services.
Since its sale by Altice in 2018, iBASIS and its global team have been dedicated to bringing Altice Dominicana best-in-class services, leveraging the group consolidation and economy of scale strategy of its owner, Tofane Global. iBASIS has helped to drive the Dominican operator’s performance, monetization, and profitability through its differentiated model, international expertise, and exclusive Inbound Gateway. Key focus areas, including cost improvement and fraud prevention, have also played a pivotal role in supporting Altice Dominicana’s sustained traffic growth.
“iBASIS demonstrated their commitment to deliver value across many facets of our international business. Their offerings and expertise, specifically in addressing international requirements, enable us to make significant service quality enhancements and cost improvements,” said Jennifer Espinal, International Business Manager at Altice Dominicana. “The strategic relationship, including the exclusive Inbound Gateway, is essential for maintaining our growth trajectory and securing our leading position in the region. We are also fortifying this collaboration and expanding into mobile services in order to capitalize on the growth of inbound roaming traffic.”
The Dominican Republic has experienced remarkable growth in tourism, witnessing a 14% increase in international visitors in 2023 compared to 2019, surpassing 10 million travelers for the first time.* Ensuring excellent roaming performance and experience is crucial in such an appealing destination for foreign visitors.
“With Altice Dominicana, we share the same goal of providing state-of-the-art connectivity and supporting innovations to unleash the potential of international communications,” said Edwin van Ierland, CEO of Voice & Mobile Data at iBASIS. “Thanks to our global platforms, capabilities, and highly motivated teams, iBASIS is a high-growth partner and is helping Altice Dominicana to continue to perform at the highest level.”
“The renewal with Altice Dominicana marks another significant milestone, highlighting the appeal of iBASIS's outsourcing proposition," remarked Alexandre Pébereau, Group CEO and Founder of Tofane Global. "By overseeing the entire spectrum of international voice and mobile communications for them, our customers can concentrate on their retail business, foster growth, and sustain their dominant market position.”
ABOUT iBASIS
iBASIS is the leading communications solutions provider enabling operators and digital players worldwide to perform and transform. Powered by Tofane Global, iBASIS is the first independent communications specialist and Tier One IPX vendor with 800+ LTE destinations. iBASIS today serves 1,000+ customers across 28 locations worldwide. iBASIS optimizes global connectivity, quality, and security so customers achieve high return on voice, SMS A2P messaging, mobile data, 5G roaming, and IoT. iBASIS provides the end-to-end Global Access for Things™ connectivity solution, delivering single source cellular IoT access (LTE, LTE-M and NB-IoT) worldwide provisioned through GSMA-standard eSIM/eUICC technology. For more information, please visit iBASIS.com.
ABOUT Altice Dominicana
Altice Dominicana is one of the main telecommunications companies in the Dominican Republic, with a decade-long history of offering connectivity and entertainment services.
Its robust mobile network has 98% coverage nationwide; With an extensive fiber optic network infrastructure, it provides Internet with the highest speed available on the market, up to 1,000 MB, cable television and high definition voice services to more than 4 million homes and businesses throughout the country.
Through its human team, agile, with challenging and daring thinking, it promotes innovation in everything it does and demonstrates its commitment to each of the Dominicans in providing them with access to technology to boost their growth opportunities.
*2023 Global Travel Trends Report
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240514293879/en/
Contact information
iBASIS Media Contact
Jason McGee-Abe
26FIVE Global Lab
iBASIS@26FIVE.com
+ 44 7970 237682
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations for treatment-resistant depression (TRD) from 10:00-11:30 am ET on January 7th. “PTSD is one of the most challenging mental health conditions, with approximately 13 million adults in the U.S. living with persistent symptoms and limited treatment options,” said Dr. Guy Goodwin, Chief Medical Officer at Compass Pathways. “We are pleased to advance our clinical development - the unmet need is profound, and it demands bold innovation. We believe COMP360 has the potential to tra
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release
I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom